Sensipar

• Calcimimetics
• ATC:H05BX01

• Sensipar

• No information avaliable

C₂₂H₂₂F₃N

http://www.rxlist.com/cgi/generic3/sensipar.htm

Sensipar FDA

No information avaliable

357.412 g/mol

No information avaliable

Slightly soluble (in HCl salt form)

Solid

6.791

Tablets (light-green, film-coated, oval-shaped tablets for oral administration in strengths of 30 mg, 60 mg, and 90 mg)

For the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis. Also for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Cinacalcet is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues). Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) is a progressive disease, associated with increases in parathyroid hormone (PTH) levels and derangements in calcium and phosphorus metabolism. Increased PTH stimulates osteoclastic activity resulting in cortical bone resorption and marrow fibrosis. The goals of treatment of secondary hyperparathyroidism are to lower levels of PTH, calcium, and phosphorus in the blood, in order to prevent progressive bone disease and the systemic consequences of disordered mineral metabolism. In CKD patients on dialysis with uncontrolled secondary HPT, reductions in PTH are associated with a favorable impact on bone-specific alkaline phosphatase (BALP), bone turnover and bone fibrosis. Cinacalcet reduces calcium levels by increasing the sensitivity of the calcium sensing receptor to extracellular calcium.

Rapidly absorbed following oral administration.

Doses titrated up to 300 mg once daily have been safely administered to patients on dialysis. Overdosage of cinacalcet may lead to hypocalcemia.

No information avaliable

Humans and other mammals